Indication

Microsatellite instability-high solid malignant tumor

A microsatellite instability-high solid malignant tumor is a cancer of non-hematologic origin defined by significant genomic hypermutability within short, repetitive DNA sequences known as microsatellites. Read more about Microsatellite instability-high solid malignant tumor

4 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Microsatellite instability-high solid malignant tumor therapies.

Showing 1–4 of 4 drugs

KEYTRUDA (pembrolizumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
Filter & compare in the drug finder →Opens the drug finder with Microsatellite instability-high solid malignant tumor preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Microsatellite instability-high solid malignant tumor.

A microsatellite instability-high solid malignant tumor is a cancer of non-hematologic origin defined by significant genomic hypermutability within short, repetitive DNA sequences known as microsatellites.

This biomarker-driven condition arises from defective cellular DNA mismatch repair (dMMR), caused either by sporadic epigenetic silencing (such as MLH1 promoter hypermethylation) or inherited germline variants associated with Lynch syndrome.

The phenotype occurs across diverse anatomical sites—most commonly in gastrointestinal and endometrial tissues—and affects both adult and pediatric populations with localized or metastatic disease.

Pathophysiologically, the failure to repair replication errors produces a markedly elevated tumor mutational burden and an abundance of frameshift-derived neoantigens, which typically elicit dense intratumoral immune infiltration.

Personalize your experience

Follow Microsatellite instability-high solid malignant tumor and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it